anonymous
Guest
anonymous
Guest
Interesting dialog on here about no fleet cars and low mileage reimbursement. I’m an R&D person so can’t speak on that. If I’m a sales person I’d be more concerned about the product. With many generic options available for MDD it will be a difficult sell. The generic options are not perfect but adequate and only cost pennies. That right there is the big challenge with trying to sell the bells and whistles of an extremely expensive treatment option in a mostly restrictive income patient population.
This is MDD, not schizophrenia. Plenty of commercial patients willing to pay a copay to go into remission from depression in 14 days and feel better in 3.